verified SJR 0,627 · Q2 • database Scopus / SJR & Web of Science indexed

United Kingdom · Sage Publications

workspace_premium Q2 — Infectious Diseases lock Subscription

Antiviral Therapy

Antiviral Therapy is a journal indexed in SJR in Infectious Diseases and Pharmacology with an H index of 94. It has an SJR impact factor of 0,627 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,627.

ISSN: 1359-6535

Publisher: Sage Publications

Category: Infectious Diseases

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

0,627 Q2

H-index 94

Acceptance rate pie_chart

25% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Subscription

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

0,627

H-index

Docs (year)

Docs 3y

108

Total refs

362

Cites 3y

195

Citable 3y

103

Cites/Doc 2y

2.11

Ref/Doc

32.91

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

—

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model

Worldwide prevalence of baseline resistance-associated polymorphisms and resistance mutations in hepatitis C virus against current direct-acting antivirals

Efficacy of tenofovir disoproxil fumarate to prevent vertical transmission in mothers with lamivudine-resistant HBV

Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistance

Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries

Effect of newer oral antiviral agents on future therapy of chronic hepatitis B

Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-a-2a therapy

Effect of HIV-infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract

Does RNA interference provide new hope for control of chronic hepatitis B infection?

Does antiviral therapy prevent hepatocellular carcinoma?

Discontinuation of lamivudine treatment in HBeAg-negative chronic hepatitis B: a pilot study with long-term follow-up

Cytolytic nanoparticles attenuate HIV-1 infectivity

SHOW MORE ARTICLES

Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B

A population analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-naive and -experienced patients

Clinical experience with intravenous zanamivir under an Emergency IND program in the United States (2011-2014)

Cerebrospinal fluid viral escape and acute encephalitis in a patient on boosted protease inhibitor monotherapy

Baseline CD4+ T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients

Avascular osteonecrosis of the femoral head in three West African HIV-infected adults with heterozygous sickle cell disease

Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population

Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection

Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety

Anti-herpes simplex virus activities of bioactive extracts from Antrodia camphorata mycelia

Anemia is associated with monocyte activation in HIV-infected adults on antiretroviral therapy

Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy

FAQs

Antiviral Therapy has an SJR of 0,627 (best quartile Q2) in the CountryOfPapers database.

Immediate OA APC is not available (NPD).

The acceptance rate recorded for Antiviral Therapy is 25%.

Antiviral Therapy

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Antiviral Therapy?

What is the APC / publication cost?

What is the acceptance rate?